1. Outcomes Associated With the Use of Secondary Prevention Medications After Coronary Artery Bypass Graft Surgery 
Abhinav Goyal, MD, MHS, John H. Alexander, MD, MHS, Gail E. Hafley, MS, Stacy H. Graham, MD, Rajendra H. Mehta, MD, MS, Michael J. Mack, MD, Randall K. Wolf, MD, Lawrence H. Cohn, MD, Nicholas T. Kouchoukos, MD, Robert A. Harrington, MD, Daniel Gennevois, MD, C. Michael Gibson, MD, Robert M. Califf, MD, T. Bruce Ferguson, MD, Eric D. Peterson, MD, MPH 
The Annals of Thoracic Surgery 
Volume 83, Issue 3, Pages (March 2007)
DOI: /j.athoracsur
Copyright © 2007 The Society of Thoracic Surgeons Terms and Conditions

2. Fig 1
Patient population. See Appendix for the definitions of ideal candidates for classes of evidence-based secondary prevention medications. (ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; MI = myocardial infarction; PREVENT IV = PRoject of Ex-vivo Vein graft ENgineering via Transfection IV trial.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2007 The Society of Thoracic Surgeons Terms and Conditions

3. Fig 2
Rates of use of secondary prevention medications among postcoronary artery bypass graft surgery patients after hospital discharge and at 1 year. Rates of medication use are shown for ideal candidates for each medication class. (ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2007 The Society of Thoracic Surgeons Terms and Conditions